These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28314310)

  • 21. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.
    Zielinski C; Lang I; Beslija S; Kahan Z; Inbar MJ; Stemmer SM; Anghel R; Vrbanec D; Messinger D; Brodowicz T
    Br J Cancer; 2016 Jan; 114(2):163-70. PubMed ID: 26657657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
    J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Brufsky AM; Hurvitz S; Perez E; Swamy R; Valero V; O'Neill V; Rugo HS
    J Clin Oncol; 2011 Nov; 29(32):4286-93. PubMed ID: 21990397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.
    Fabi A; Russillo M; Ferretti G; Metro G; Nisticò C; Papaldo P; De Vita F; D'Auria G; Vidiri A; Giannarelli D; Cognetti F
    BMC Cancer; 2012 Oct; 12():482. PubMed ID: 23083011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial.
    Masuda N; Takahashi M; Nakagami K; Okumura Y; Nakayama T; Sato N; Kanatani K; Tajima K; Kashiwaba M
    Jpn J Clin Oncol; 2017 May; 47(5):385-392. PubMed ID: 28158579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer.
    Wu Q; Wang X; Zhang M; Liao W; Wang F; Li Q
    Oncol Res Treat; 2020; 43(4):153-159. PubMed ID: 32187596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
    Claessens AKM; Bos MEMM; Lopez-Yurda M; Bouma JM; Rademaker-Lakhai JM; Honkoop AH; de Graaf H; van Druten E; van Warmerdam LJC; van der Sangen MJC; Tjan-Heijnen VCG; Erdkamp FLG;
    Breast Cancer Res Treat; 2018 Nov; 172(2):413-423. PubMed ID: 30121808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.
    Chen XL; Du F; Hong RX; Wang JY; Luo Y; Li Q; Fan Y; Xu BH
    Chin J Cancer; 2016 Apr; 35():39. PubMed ID: 27112139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons.
    Sini V; Cassano A; Corsi D; De Laurentiis M; Gamucci T; Mauri M; Naso G; Roselli M; Ruggeri EM; Tonini G; Vici P; Zampa G; Marchetti P
    Tumori; 2016 Oct; 102(5):472-480. PubMed ID: 27647231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.
    Diéras V; Wildiers H; Jassem J; Dirix LY; Guastalla JP; Bono P; Hurvitz SA; Gonçalves A; Romieu G; Limentani SA; Jerusalem G; Lakshmaiah KC; Roché H; Sánchez-Rovira P; Pienkowski T; Seguí Palmer MÁ; Li A; Sun YN; Pickett CA; Slamon DJ
    Breast; 2015 Jun; 24(3):182-90. PubMed ID: 25747197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.
    Hamilton E; Kimmick G; Hopkins J; Marcom PK; Rocha G; Welch R; Broadwater G; Blackwell K
    Clin Breast Cancer; 2013 Dec; 13(6):416-20. PubMed ID: 24099649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study.
    Müller V; Ruhnke M; Hoffmann O; Grafe A; Tomé O; Fett W; Bruch HR; Sommer-Joos AK; Schneeweiss A
    Breast; 2021 Dec; 60():70-77. PubMed ID: 34488065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
    von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
    Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience.
    Livi L; Bonomo P; Meattini I; Simontacchi G; Greto D; Desideri I; Meacci F; Scotti V; Cecchini S; Nori J; Sanchez LJ; Orzalesi L; Paiar F; Biti G
    Med Oncol; 2013 Mar; 30(1):434. PubMed ID: 23283649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
    Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
    Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.
    Fountzilas G; Kourea HP; Bobos M; Televantou D; Kotoula V; Papadimitriou C; Papazisis KT; Timotheadou E; Efstratiou I; Koutras A; Pentheroudakis G; Christodoulou C; Aravantinos G; Miliaras D; Petraki K; Papandreou CN; Papakostas P; Bafaloukos D; Repana D; Razis E; Pectasides D; Dimopoulos AM
    Anticancer Res; 2011 Sep; 31(9):3007-18. PubMed ID: 21868552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintenance Therapy in HER2-Negative Metastatic Breast Cancer: A New Approach for an Old Concept.
    Ciruelos E; Pérez-García JM; Gavilá J; Rodríguez A; de la Haba-Rodriguez J
    Clin Drug Investig; 2019 Jul; 39(7):595-606. PubMed ID: 31054086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preoperative carboplatin-paclitaxel-bevacizumab in triple-negative breast cancer: final results of the phase II Ca.Pa.Be study.
    Guarneri V; Dieci MV; Bisagni G; Boni C; Cagossi K; Puglisi F; Pecchi A; Piacentini F; Conte P
    Ann Surg Oncol; 2015 Sep; 22(9):2881-7. PubMed ID: 25572687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies.
    Yamamoto Y; Yamashiro H; Schneeweiss A; Müller V; Gluz O; Klare P; Aktas B; Magdolna D; Büdi L; Pikó B; Mangel L; Toi M; Morita S; Ohno S
    Breast Cancer; 2023 Jan; 30(1):88-100. PubMed ID: 36057014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel.
    Mendiola M; Martínez-Marin V; Herranz J; Heredia V; Yébenes L; Zamora P; Castelo B; Pinto Á; Miguel M; Díaz E; Gámez A; Fresno JÁ; Ramírez de Molina A; Hardisson D; Espinosa E; Redondo A
    Oncotarget; 2016 Apr; 7(17):24217-27. PubMed ID: 26992213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.